Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominik Paul

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Anticancer Research|October 3, 2022
Retrospective Analysis of Treatment Pathways in Patients With BRAF<sup>V600E</sup>-mutant Metastatic Colorectal Carcinoma - MORSE<sup>CRC</sup>Armin Gerger, Wolfgang Eisterer, Stefan Fuxius, et al.
European Journal of Radiology|May 11, 2026
Aorta and coronary artery assessment using high-contrast respiratory motion corrected and ECG-gated 3D T2-prepared GRE MRI with Dixon fat-water separation in patients with and without prior aortic root surgery at 3 TGrazia Maria Cereghetti, Levin Patrick Huber, Inga Todorski, et al.
Journal of the National Cancer Institute|May 24, 2026
Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancerAlessandra Raimondi, Gabriele Tinè, Valerie Boige, et al.
Oncotarget|December 30, 2017
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Annals of Surgical Oncology|March 16, 2020
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306Dominik Paul Modest, Volker Heinemann, Gunnar Folprecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory <i>KRAS</i> G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2022
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314)Dominik Paul Modest, Meinolf Karthaus, Stefan Kasper, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 2, 2026
Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO trialAdrien Grancher, Matteo Landi, Alexej Ballhausen, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF<sup>V600E</sup>-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)Lena Weiss, Sebastian Stintzing, Dominik Paul Modest, et al.
The Lancet. Oncology|August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trialDominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Anticancer Research|October 3, 2022
Retrospective Analysis of Treatment Pathways in Patients With BRAF<sup>V600E</sup>-mutant Metastatic Colorectal Carcinoma - MORSE<sup>CRC</sup>Armin Gerger, Wolfgang Eisterer, Stefan Fuxius, et al.
European Journal of Radiology|May 11, 2026
Aorta and coronary artery assessment using high-contrast respiratory motion corrected and ECG-gated 3D T2-prepared GRE MRI with Dixon fat-water separation in patients with and without prior aortic root surgery at 3 TGrazia Maria Cereghetti, Levin Patrick Huber, Inga Todorski, et al.
Journal of the National Cancer Institute|May 24, 2026
Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancerAlessandra Raimondi, Gabriele Tinè, Valerie Boige, et al.
Oncotarget|December 30, 2017
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Annals of Surgical Oncology|March 16, 2020
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306Dominik Paul Modest, Volker Heinemann, Gunnar Folprecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory <i>KRAS</i> G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2022
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314)Dominik Paul Modest, Meinolf Karthaus, Stefan Kasper, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 2, 2026
Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO trialAdrien Grancher, Matteo Landi, Alexej Ballhausen, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF<sup>V600E</sup>-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)Lena Weiss, Sebastian Stintzing, Dominik Paul Modest, et al.
The Lancet. Oncology|August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trialDominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
Pageof 10